Unknown Analyst
Lynn, to start here, could you give us an overview of where your two oncology programs stand today and how to think about the catalyst path as we look to second half and beyond?
Lynn Seely
Principal Executive Officer, President, CEO & Director
Absolutely. Well, I will be making forward-looking statements here today. So Lyell is a cell therapy company focused on next-generation cell therapies for cancer, and we have two programs in the clinic. One is a dual-targeting CD19/CD20 CAR T-cell program for large B-cell lymphoma, where we are in pivotal trials. We have a single-arm pivotal trial underway where we’re going to be providing a major data update in the second half of this year.
That will be the last look before the pivotal data are expected mid next year, and then we’ll be following with an expected BLA submission before the end of the year. So we’re really excited about that. And then, of course, we have started and are actively recruiting patients into the first of its kind head-to-head trial of CAR T-cell therapy, Ronde-cel, our program versus investigators’ choice of one of the two approved CD19 CARs, Yescarta or Breyanzi.
And then in addition to the Ronde-cel program, we have LYL273, which is a GCC-targeted novel CAR for patients with metastatic colorectal cancer. So we’re really excited about our progress on both programs.
Unknown Analyst
For Ronde-cel to start there, your lead program, it’s currently in registrational trials, as
Credit: Source link
